Last week the Enzolytics Inc (OTCMKTS:ENZC) stock suffered a slight decline and ended with a loss of 22% last week. However, at the same time, it should be noted that there was no news about the company that might have triggered the selloff last week. In this situation, it might be a good move for investors to perhaps take a look at a development from last month.
At the time, the company announced that it concluded the agreements and arrangements with Clinic Design and Danhson for the purpose of taking forward its anti-HIV therapeutic product ITV-1. Enzolytics is looking to get to the production and clinical trial stages of the process through these tie ups.
The company announced at the time that the steps that it took were prefatory to the approval it had received for the product from the European Medicines Agency. As per the terms of the agreement, Danhson is going to help the company with the production process by allowing the use of its own facilities. On the other hand, the clinical trials are going to be facilitated by Clinic Design. These were important developments and could help Enzolytics in speeding up its program considerably.
